Avacta reports clinical proof of mechanism for AVA6103 cancer drug
AI Summary- Avacta reported clinical proof of mechanism for AVA6103 in the Phase 1 FOCUS-01 trial.
- 19 patients completed enrollment across the first three dose levels, ranging from 1.5 to 4.5 mg/m2.
- FOCUS-01 continues enrolling patients at dose level 4 in its two dosing schedules.